Experience of using prolgolimab in real clinical practice

作者: Protsenko S.A¹, Imyanitov E.N¹^,2, Malygin A.Y.¹, Yurlov D.O¹, Semenova A.I¹, Latipova D.K.¹, Novik A.V¹^,2, Teletaeva G.M¹, Zinoviev G.V¹, Ebert M.A¹^,2, Artemieva A.S¹, Baldueva I.A¹
隶属关系:
1. N.N. Petrov National Medical Research Center of Oncology
2. Saint Petersburg State Pediatric Medical University
期: 卷 28, 编号 7 (2021)
页面: 51-55
栏目: Articles
URL: https://journals.eco-vector.com/2073-4034/article/view/313178
DOI: https://doi.org/10.18565/pharmateca.2021.7.51-55
ID: 313178

如何引用文章

全文:

开放存取

开放存取

受限制的访问

##reader.subscriptionAccessGranted##
受限制的访问

受限制的访问

订阅或者付费存取

详细
全文:
作者简介
参考
补充文件
统计

详细

Melanoma of the skin is one of the most aggressive malignant neoplasms. Approaches to the treatment of metastatic skin melanoma have been dynamically developing over the past decade. The first original IgG1 anti-PD-lmonoclonal antibody containing the Fc-silencing ‘LALA’ mutation has been developed in Russia. This article demonstrates our own experience of using the domestic PD-1 inhibitor prolgolimab in clinical practice.

关键词

neoadjuvant immunotherapy, immuno-oncology, PD-1 inhibitors, prolgolimab

全文:

受限制的访问

作者简介

S. Protsenko

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

E. Imyanitov

N.N. Petrov National Medical Research Center of Oncology; Saint Petersburg State Pediatric Medical University

St. Petersburg, Russia

A. Malygin

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

D. Yurlov

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

A. Semenova

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

D. Latipova

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

A. Novik

N.N. Petrov National Medical Research Center of Oncology; Saint Petersburg State Pediatric Medical University

St. Petersburg, Russia

G. Teletaeva

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

G. Zinoviev

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

M. Ebert

N.N. Petrov National Medical Research Center of Oncology; Saint Petersburg State Pediatric Medical University

St. Petersburg, Russia

A. Artemieva

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

I. Baldueva

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

参考

Tjulandin S., Fedyanin M., Semiglazova T., et al. BCD-100 - first Russian PD-1 inhibitor. J Mod Oncol. 2017;19:13-20.
Tjulandin S., et al. Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice. Eur J Cancer. 2021;149:222-32. doi: 10.1016/j.ejca.2021.02.030.
Rozeman E.A., et al. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nat Med. 2021; 27(2):256-63. doi: 10.1038/s41591-020- 01211-7
Blank C.U., Reijers I.L.M., Pennington T., et al. First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma. J Clin Oncol. 2020;38;15S. URL: https://meetinglibrary.asco.org/record/185836/ abstract
Krishnamoorthy M., Lenehan J.G., Vareki S.M. Neoadjuvant Immunotherapy for High-Risk, Resectable Malignancies: Scientific Rationale and Clinical Challenges, JNCI: J Nation Cancer Inst. 2021, djaa216. doi: 10.1093/jnci/djaa216. 7-y
Huang A.C., et al.Asingledose ofneoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat. Med. 2019;25(3):454-61. doi: 10.1038/s41591-019-0357-y

补充文件

附件文件

动作

1. JATS XML

版权所有 © Bionika Media, 2021

##common.cookie##

TOP